237
Views
3
CrossRef citations to date
0
Altmetric
Original Articles: Research

Evaluation of the cytotoxic response mediated by perforin and granzyme B in patients with non-Hodgkin lymphoma

ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 214-220 | Received 13 Dec 2016, Accepted 05 Jun 2017, Published online: 06 Jul 2017

References

  • Smyth MJ, Trapani JA. Granzymes: exogenous proteinases that induce target cell apoptosis. Immunol Today. 1995;16:202–206.
  • Voskoboinik I, Thia MC, Trapani JA. A functional analysis of the putative polymorphisms A91V and N252S and 22 missense perforin mutations associated with familial hemophagocytic lymphohistiocytosis. Blood. 2005;105:4700–4706.
  • Solomou EE, Gibellini F, Stewart B, et al. Perforin gene mutations in patients with acquired aplastic anemia. Blood. 2007;109:5234–5237.
  • Santoro A, Cannella S, Trizzino A, et al. A single amino acid change A91V in perforin: a novel, frequent predisposing factor to childhood acute lymphoblastic leukemia? Haematologica. 2005;90:697–698.
  • Clementi R, Locatelli F, Dupré L, et al. A proportion of patients with lymphoma may harbor mutations of the perforin gene. Blood. 2005;105:4424–4428.
  • Cannella S, Santoro A, Bruno G, et al. Germline mutations of the perforin gene are a frequent occurrence in childhood anaplastic large cell lymphoma. Cancer. 2007;109:2566–2571.
  • van den Broek ME, Kägi D, Ossendorp F, et al. Decreased tumor surveillance in perforin-deficient mice. J Exp Med. 1996;184:1781–1790.
  • Smyth MJ, Thia KY, Street SE, et al. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma. J Exp Med. 2000;192:755–760.
  • Brennan AJ, Chia J, Trapani JA, et al. Perforin deficiency and susceptibility to cancer. Cell Death Differ. 2010;17:607–615.
  • Mullbacher A, Waring P, Tha Hla R, et al. Granzymes are the essential downstream effector molecules for the control of primary virus infections by cytolytic leukocytes. Proc Natl Acad Sci USA. 1999;96:13950–13955.
  • Shresta S, Graubert TA, Thomas DA, et al. Granzyme A initiates an alternative pathway for granule-mediated apoptosis. Immunity. 1999;10:595–605.
  • Revell PA, Grossman WJ, Thomas DA, et al. Granzyme B and the downstream granzymes C and/or F are important for cytotoxic lymphocyte functions. J Immunol. 2005;174:2124–2131.
  • Voskoboinik I, Whisstock JC, Trapani JA. Perforin and granzymes: function, dysfunction and human pathology. Nat Rev Immunol. 2015;15:388–400.
  • Martínez-Pomar N, Lanio N, Romo N, et al. Functional impact of A91V mutation of the PRF1 perforin gene. Hum Immunol. 2013;74:14–17.
  • Xu L, Chen D, Lu C, et al. Advanced lung cancer is associated with decreased expression of perforin, CD95, CD38 by circulating CD3 + CD8+ T lymphocytes. Ann Clin Lab Sci. 2015;45:528–532.
  • Chang C, Lin CH, Cheng AL, et al. Primary central nervous system diffuse large B-cell lymphoma has poorer immune cell infiltration and prognosis than its peripheral counterpart. Histopathology. 2015;67:625–635.
  • Baychelier F, Achour A, Nguyen S, et al. Natural killer cell deficiency in patients with non-Hodgkin lymphoma after lung transplantation. J Heart Lung Transplant. 2015;34:604–612.
  • Bose A, Chakraborty T, Chakraborty K, et al. Dysregulation in immune functions is reflected in tumor cell cytotoxicity by peripheral blood mononuclear cells from head and neck squamous cell carcinoma patients. Cancer Immun. 2008;12:8–10.
  • Kamarashev J, Burg G, Mingari MC, et al. Differential expression of cytotoxic molecules and killer cell inhibitory receptors in CD8+ and CD56+ cutaneous lymphomas. Am J Pathol. 2001;158:1593–1598.
  • Hejazi M, Manser AR, Fröbel J, et al. Impaired cytotoxicity associated with defective natural killer cell differentiation in myelodysplastic syndromes. Haematologica. 2015;100:643–652.
  • Fehniger TA, Cai SF, Cao X, et al. Acquisition of murine NK cell cytotoxicity requires the translation of a pre-existing pool of granzyme B and perforin mRNAs. Immunity. 2007;26:798–811.
  • Pipkin ME, Rao A, Lichtenheld MG. The transcriptional control of the perforin locus. Immunol Rev. 2010;235:55–72.
  • Kawasaki A, Shinkai Y, Yagita H, et al. Expression of perforin in murine natural killer cells and cytotoxic T lymphocytes in vivo. Eur J Immunol. 1992;22:1215–1219.
  • Salcedo TW, Azzoni L, Wolf SF, et al. Modulation of perforin and granzyme messenger RNA expression in human natural killer cells. J Immunol. 1993;151:2511–2520.
  • Busiello R, Fimiani G, Miano MG, et al. A91V perforin variation in healthy subjects and FHLH patients. Int J Immunogenet. 2006;33:123–125.
  • House IG, Thia K, Brennan AJ, et al. Heterozygosity for the common perforin mutation, p.A91V, impairs the cytotoxicity of primary natural killer cells from healthy individuals. Immunol Cell Biol. 2015;93:575–580.
  • Arora M, Gowda S, Tuscano J. A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma. Ther Adv Hematol. 2016;7:209–221.
  • Galanina N, Petrich A, Nabhan C. The evolving role of lenalidomide in non-Hodgkin lymphoma. Leuk Lymphoma. 2016;57:1507–1516.
  • Ruan J, Shah B, Martin P, et al. Clinical experience with lenalidomide alone or in combination with rituximab in indolent B-cell and mantle cell lymphomas. Ann Oncol. 2016;27:1226–1234.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.